Top

Cancer Chemotherapy and Pharmacology

Published in:

01-12-2019 | Radiotherapy | Original Article

Upregulation of miR-519 enhances radiosensitivity of esophageal squamous cell carcinoma trough targeting PI3K/AKT/mTOR signaling pathway

Authors: Yanshan Zhang, Weizuo Chen, Huijuan Wang, Tingting Pan, Yinguo Zhang, Chao Li

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2019

Abstract

Purpose

MicroRNA-519 (miR-519) has been previously reported to function as a tumor suppressor in several types of malignancies. This study aimed to probe the biological role of miR-519 in esophageal squamous cell carcinoma (ESCC).

Methods

qRT-PCR was utilized to test the miR-519 expression level in ESCC tissues and cells. Clinical value of miR-519 was investigated by Kaplan–Meier method. Function assays were conducted to determine the role of miR-519 in radioresistance of ESCC cells. The miR-519-regulated pathways were determined by Kyoto Encyclopedia of Genes and Genomes pathway analysis.

Results

Low expression level of miR-519 was closely correlated with the poor prognosis for overall survival of ESCC patients or patients who received radiotherapy. Functional assays indicated that upregulation of miR-519 made ESCC cells more sensitive to γ-ray radiation and facilitated ESCC cell apoptosis triggered by irradiation treatment via regulating DNA response. Ectopic expression of miR-519 decreased the level of p-AKT and p-mTOR, thus inactivating PI3K/AKT/mTOR signaling pathway after irradiation.

Conclusion

These observations elucidated that upregulated miR-519 is closely correlated with the radiosensitivity of ESCC cells, which may contribute to finding a new promising target for improving the efficiency of radiotherapy in patients with ESCC.

Available only for authorised users

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492 CrossRef

Berger B, Belka C (2009) Evidence-based radiation oncology: oesophagus. Radiother Oncol 92(2):276–290. https://doi.org/10.1016/j.radonc.2009.02.019 CrossRefPubMed

Nakajima M, Kato H (2013) Treatment options for esophageal squamous cell carcinoma. Expert Opin Pharmacother 14(10):1345–1354CrossRef

Borghesi S, Hawkins MA, Tait D (2008) Oesophagectomy after definitive chemoradiation in patients with locally advanced oesophageal cancer. Clin Oncol (R Coll Radiol) 20(3):221–226. https://doi.org/10.1016/j.clon.2007.12.001 CrossRef

Minsky B, Pajak T, Ginsberg R, Pisansky T, Martenson J, Komaki R, Okawara G, Rosenthal S, Kelsen D (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20(5):1167–1174CrossRef

Bartel D (2004) MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116(2):281–297CrossRef

Papagiannakopoulos T, Kosik KS (2008) MicroRNAs: regulators of oncogenesis and stemness. BMC Med 6:15. https://doi.org/10.1186/1741-7015-6-15 CrossRefPubMedPubMedCentral

Palanichamy JK, Rao DS (2014) miRNA dysregulation in cancer: towards a mechanistic understanding. Front Genet 5:54. https://doi.org/10.3389/fgene.2014.00054 CrossRefPubMedPubMedCentral

Dong Y, Zheng Y, Wang C, Ding X, Du Y, Liu L, Zhang W, Zhang W, Zhong Y, Wu Y, Song X (2018) MiR-876-5p modulates head and neck squamous cell carcinoma metastasis and invasion by targeting vimentin. Cancer Cell Int 18:121CrossRef

10.

Song L, Dai Z, Zhang S, Zhang H, Liu C, Ma X, Liu D, Zan Y, Yin X (2018) MicroRNA-1179 suppresses cell growth and invasion by targeting sperm-associated antigen 5-mediated Akt signaling in human non-small cell lung cancer. Biochem Biophys Res Commun 504(1):164–170CrossRef

11.

Xu J, Wang F, Wang X, He Z, Zhu X (2018) miRNA-543 promotes cell migration and invasion by targeting SPOP in gastric cancer. Onco Targets Ther 11:5075–5082CrossRef

12.

Wang L, Yu P, Li B, Guo Y, Liang Z, Zheng L, Yang J, Xu H, Liu S, Zheng L, Zhou H, Qu L (2018) miR-372 and miR-373 enhance the stemness of colorectal cancer cells by repressing differentiation signaling pathways. Mol Oncol 12(11):1949–1964CrossRef

13.

Zhou S, Ye W, Ren J, Shao Q, Qi Y, Liang J, Zhang M (2015) MicroRNA-381 increases radiosensitivity in esophageal squamous cell carcinoma. Am J Cancer Res 5(1):267–277PubMed

14.

Zheng R, Liu Y, Zhang X, Zhao P, Deng Q (2017) miRNA-200c enhances radiosensitivity of esophageal cancer by cell cycle arrest and targeting P21. Biomed Pharmacother 90:517–523. https://doi.org/10.1016/j.biopha.2017.04.006 CrossRefPubMed

15.

Yu G, Zhang T, Jing Y, Bao Q, Tang Q, Zhang Y (2017) miR-519 suppresses nasopharyngeal carcinoma cell proliferation by targeting oncogene URG4/URGCP. Life Sci 175:47–51. https://doi.org/10.1016/j.lfs.2017.03.010 CrossRefPubMed

16.

Deng W, Wang J, Zhang J, Cai J, Bai Z, Zhang Z (2016) Orai1, a direct target of microRNA-519, promotes progression of colorectal cancer via Akt/GSK3beta signaling pathway. Dig Dis Sci 61(6):1553–1560. https://doi.org/10.1007/s10620-015-4029-6 CrossRefPubMed

17.

Abdelmohsen K, Srikantan S, Kuwano Y, Gorospe M (2008) miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. Proc Natl Acad Sci USA 105(51):20297–20302CrossRef

18.

Abdelmohsen K, Kim MM, Srikantan S, Mercken EM, Brennan SE, Wilson GM, Cabo R, Gorospe M (2010) miR-519 suppresses tumor growth by reducing HuR levels. Cell Cycle 9(7):1354–1359. https://doi.org/10.4161/cc.9.7.11164 CrossRefPubMedPubMedCentral

19.

Abdelmohsen K, Srikantan S, Tominaga K, Kang MJ, Yaniv Y, Martindale JL, Yang X, Park SS, Becker KG, Subramanian M, Maudsley S, Lal A, Gorospe M (2012) Growth inhibition by miR-519 via multiple p21-inducing pathways. Mol Cell Biol 32(13):2530–2548. https://doi.org/10.1128/MCB.00510-12 CrossRefPubMedPubMedCentral

20.

Cheng G (2015) Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev 81:75–93. https://doi.org/10.1016/j.addr.2014.09.001 CrossRefPubMed

21.

He H, Hao SJ, Yao L, Yang F, Di Y, Li J, Jiang YJ, Jin C, Fu DL (2014) MicroRNA-218 inhibits cell invasion and migration of pancreatic cancer via regulating ROBO1. Cancer Biol Ther 15(10):1333–1339. https://doi.org/10.4161/cbt.29706 CrossRefPubMedPubMedCentral

22.

Xu W, Hang M, Yuan C, Wu F, Chen S, Xue K (2015) MicroRNA-139-5p inhibits cell proliferation and invasion by targeting insulin-like growth factor 1 receptor in human non-small cell lung cancer. Int J Clin Exp Pathol 8(4):3864–3870PubMedPubMedCentral

23.

Li S-P, Su H-X, Zhao D, Guan Q-L (2016) Plasma miRNA-506 as a prognostic biomarker for esophageal squamous cell carcinoma. Med Sci Monit 22:2195–2201. https://doi.org/10.12659/msm.899377 CrossRefPubMedPubMedCentral

24.

Yu T, Cao R, Li S, Fu M, Ren L, Chen W, Zhu H, Zhan Q, Shi R (2015) MiR-130b plays an oncogenic role by repressing PTEN expression in esophageal squamous cell carcinoma cells. BMC Cancer 15:29. https://doi.org/10.1186/s12885-015-1031-5 CrossRefPubMedPubMedCentral

25.

Chaudhry MA (2014) Radiation-induced microRNA: discovery, functional analysis, and cancer radiotherapy. J Cell Biochem 115(3):436–449. https://doi.org/10.1002/jcb.24694 CrossRefPubMed

26.

Hayes J, Peruzzi PP, Lawler S (2014) MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med 20(8):460–469. https://doi.org/10.1016/j.molmed.2014.06.005 CrossRefPubMed

27.

Metheetrairut C, Slack FJ (2013) MicroRNAs in the ionizing radiation response and in radiotherapy. Curr Opin Genet Dev 23(1):12–19. https://doi.org/10.1016/j.gde.2013.01.002 CrossRefPubMedPubMedCentral

28.

Yu X, Li Z, Yu J, Chan MT, Wu WK (2015) MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer. Cell Prolif 48(5):503–510. https://doi.org/10.1111/cpr.12202 CrossRefPubMed

29.

Zhang XL, Shi HJ, Wang JP, Tang HS, Wu YB, Fang ZY, Cui SZ, Wang LT (2014) MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin. World J Gastroenterol 20(32):11347–11355. https://doi.org/10.3748/wjg.v20.i32.11347 CrossRefPubMedPubMedCentral

30.

Wang XC, Zhang ZB, Wang YY, Wu HY, Li DG, Meng AM, Fan FY (2013) Increased miRNA-22 expression sensitizes esophageal squamous cell carcinoma to irradiation. J Radiat Res 54(3):401–408. https://doi.org/10.1093/jrr/rrs113 CrossRefPubMed

31.

Park M, Yoon HJ, Kang MC, Kwon J, Lee HW (2017) MiR-338-5p enhances the radiosensitivity of esophageal squamous cell carcinoma by inducing apoptosis through targeting survivin. Sci Rep 7(1):10932. https://doi.org/10.1038/s41598-017-10977-9 CrossRefPubMedPubMedCentral

32.

Fukuda K, Sakakura C, Miyagawa K, Kuriu Y, Kin S, Nakase Y, Hagiwara A, Mitsufuji S, Okazaki Y, Hayashizaki Y, Yamagishi H (2004) Differential gene expression profiles of radioresistant oesophageal cancer cell lines established by continuous fractionated irradiation. Br J Cancer 91(8):1543–1550. https://doi.org/10.1038/sj.bjc.6602187 CrossRefPubMedPubMedCentral

33.

Kitahara O, Katagiri T, Tsunoda T, Harima Y, Nakamura Y (2002) Classification of sensitivity or resistance of cervical cancers to ionizing radiation according to expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia 4(4):295–303. https://doi.org/10.1038/sj.neo.7900251 CrossRefPubMedPubMedCentral

34.

Liu G, Song Y, Cui L, Wen Z, Lu X (2015) Inositol hexaphosphate suppresses growth and induces apoptosis in HT-29 colorectal cancer cells in culture: PI3K/Akt pathway as a potential target. Int J Clin Exp Pathol 8(2):1402–1410PubMedPubMedCentral

35.

Li H, Hu J, Wu S, Wang L, Cao X, Zhang X, Dai B, Cao M, Shao R, Zhang R, Majidi M, Ji L, Heymach JV, Wang M, Pan S, Minna J, Mehran RJ, Swisher SG, Roth JA, Fang B (2016) Auranofin-mediated inhibition of PI3K/AKT/mTOR axis and anticancer activity in non-small cell lung cancer cells. Oncotarget 7(3):3548–3558. https://doi.org/10.18632/oncotarget.6516 CrossRefPubMed

36.

Yang XX, Ma M, Sang MX, Zhang XY, Liu ZK, Song H, Zhu SC (2018) BMI-1 suppression increases the radiosensitivity of oesophageal carcinoma via the PI3K/Akt signaling pathway. Oncol Rep 39(2):667–678. https://doi.org/10.3892/or.2017.6136 CrossRefPubMed

37.

Chang L, Graham PH, Hao J, Ni J, Bucci J, Cozzi PJ, Kearsley JH, Li Y (2014) PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis 5:e1437. https://doi.org/10.1038/cddis.2014.415 CrossRefPubMedPubMedCentral

Title: Upregulation of miR-519 enhances radiosensitivity of esophageal squamous cell carcinoma trough targeting PI3K/AKT/mTOR signaling pathway
Authors: Yanshan Zhang
Weizuo Chen
Huijuan Wang
Tingting Pan
Yinguo Zhang
Chao Li
Publication date: 01-12-2019
Publisher: Springer Berlin Heidelberg
Keyword: Radiotherapy
Published in: Cancer Chemotherapy and Pharmacology / Issue 6/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-019-03922-2

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Image Credits

ASCO 2024 | Highlights of the Day: Breast cancer – metastatic/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Gynecologic Cancer/© 2024 American Society of Clinical Oncology, all rights reserved., ASCO 2024 | Highlights of the Day: Breast Cancer – local/regional/adjuvant/© 2024 American Society of Clinical Oncology, all rights reserved., Melanoma/© selvanegra / Getty Images / iStock, Antibody drug conjugated with cytotoxic payload/© Love Employee / Getty images / iStock

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2019

A phase I delayed-start, randomized and pharmacodynamic study of metformin and chemotherapy in patients with solid tumors

Combined thermo-chemotherapy of cancer using 1 MHz ultrasound waves and a cisplatin-loaded sonosensitizing nanoplatform: an in vivo study

Metformin plus first-line chemotherapy versus chemotherapy alone in the treatment of epithelial ovarian cancer: a prospective open-label pilot trial

NO donor inhibits proliferation and induces apoptosis by targeting PI3K/AKT/mTOR and MEK/ERK pathways in hepatocellular carcinoma cells

Dihydropyrimidine dehydrogenase in the metabolism of the anticancer drugs